Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 73 Ovarian Neoplasms 46 Lung Neoplasms 26 Breast Neoplasms 26 Fallopian Tube Neoplasms 23 Small Cell Lung Carcinoma 18 Carcinoma, Ovarian Epithelial 16 Squamous Cell Carcinoma of Head and Neck 14 Neoplasms 14 Glioblastoma 13 Triple Negative Breast Neoplasms 12 Recurrence 11 Head and Neck Neoplasms 11 Lymphoma, Large B-Cell, Diffuse 10 Endometrial Neoplasms 10 Uterine Cervical Neoplasms 9 Colorectal Neoplasms 9 Stomach Neoplasms 8 Hodgkin Disease 8 Brain Neoplasms 8 Lymphoma 7 Esophageal Neoplasms 7 Central Nervous System Neoplasms 7 Prostatic Neoplasms 6 Neoplasm Metastasis 6 Glioma 6 Esophageal Squamous Cell Carcinoma 6 Astrocytoma 6 Adenocarcinoma of Lung 6 Mesothelioma 5

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cancer Related Cognitive Decline × Carboplatin × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡